BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 16234527)

  • 21. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
    Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
    J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.
    Fleming AJ; Smith SP; Paul CM; Hall NC; Daly BT; Agrawal A; Schuller DE
    Laryngoscope; 2007 Jul; 117(7):1173-9. PubMed ID: 17603315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
    Nishizawa S; Kojima S; Teramukai S; Inubushi M; Kodama H; Maeda Y; Okada H; Zhou B; Nagai Y; Fukushima M
    J Clin Oncol; 2009 Apr; 27(11):1767-73. PubMed ID: 19255324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.
    Agress H; Cooper BZ
    Radiology; 2004 Feb; 230(2):417-22. PubMed ID: 14699176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical significance of 18F-FDG-PET/CT in early detection of second primary malignancy in cancer patients.
    Xu H; Zhang M; Zhai G; Li B
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1125-34. PubMed ID: 20091320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second cancers discovered by (18)FDG PET/CT imaging for choroidal melanoma.
    Chin K; Finger PT; Kurli M; Tena LB; Reddy S
    Optometry; 2007 Aug; 78(8):396-401. PubMed ID: 17662928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
    Antoch G; Vogt FM; Freudenberg LS; Nazaradeh F; Goehde SC; Barkhausen J; Dahmen G; Bockisch A; Debatin JF; Ruehm SG
    JAMA; 2003 Dec; 290(24):3199-206. PubMed ID: 14693872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary.
    Freudenberg LS; Fischer M; Antoch G; Jentzen W; Gutzeit A; Rosenbaum SJ; Bockisch A; Egelhof T
    Med Princ Pract; 2005; 14(3):155-60. PubMed ID: 15863988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.